✦ LIBER ✦

Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial

✍ Scribed by Lawitz, Eric; Lalezari, Jay P; Hassanein, Tarek; Kowdley, Kris V; Poordad, Fred F; Sheikh, Aasim M; Afdhal, Nezam H; Bernstein, David E; DeJesus, Edwin; Freilich, Bradley; Nelson, David R; Dieterich, Douglas T; Jacobson, Ira M; Jensen, Donald; Abrams, Gary A; Darling, Jama M; Rodriguez-Torres, Maribel; Reddy, K Rajender; Sulkowski, Mark S; Bzowej, Natalie H; Hyland, Robert H; Mo, Hongmei; Lin, Ming; Mader, Michael; Hindes, Robert; Albanis, Efsevia; Symonds, William T; Berrey, Michelle M; Muir, Andrew

Book ID: 121230344
Publisher: The Lancet
Year: 2013
Tongue: English
Weight: 276 KB
Volume: 13
Category: Article
ISSN: 1473-3099
DOI: 10.1016/S1473-3099(13)70033-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Sofosbuvir with pegylated interferon alf

Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial

✍ Kowdley, Kris V; Lawitz, Eric; Crespo, Israel; Hassanein, Tarek; Davis, Mitchell 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 241 KB

Simeprevir with pegylated interferon alf

Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial

✍ Manns, Michael; Marcellin, Patrick; Poordad, Fred; de Araujo, Evaldo Stanislau A 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 287 KB

Simeprevir with pegylated interferon alf

Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial

✍ Jacobson, Ira M; Dore, Gregory J; Foster, Graham R; Fried, Michael W; Radu, Moni 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 284 KB

Efficacy of boceprevir, an NS3 protease

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

✍ Paul Y Kwo; Eric J Lawitz; Jonathan McCone; Eugene R Schiff; John M Vierling; Da 📂 Article 📅 2010 🏛 The Lancet 🌐 English ⚖ 378 KB

Faldaprevir combined with peginterferon

Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial

✍ Sulkowski, Mark S.; Bourlière, Marc; Bronowicki, Jean-Pierre; Asselah, Tarik; Pa 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 599 KB

Boceprevir versus placebo with pegylated

Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial

✍ Sulkowski, Mark; Pol, Stanislas; Mallolas, Josep; Fainboim, Hugo; Cooper, Curtis 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 333 KB